Your browser doesn't support javascript.
loading
The Clinical and Economic Impact of Measles-Mumps-Rubella Vaccinations to Prevent Measles Importations From US Pediatric Travelers Returning From Abroad.
Bangs, Audrey C; Gastañaduy, Paul; Neilan, Anne M; Fiebelkorn, Amy Parker; Walker, Allison Taylor; Rao, Sowmya R; Ryan, Edward T; LaRocque, Regina C; Walensky, Rochelle P; Hyle, Emily P.
Afiliação
  • Bangs AC; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Gastañaduy P; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Neilan AM; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Fiebelkorn AP; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Walker AT; Division of General Academic Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Rao SR; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Ryan ET; Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • LaRocque RC; Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Walensky RP; MGH Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Hyle EP; Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.
J Pediatric Infect Dis Soc ; 11(6): 257-266, 2022 Jun 22.
Article em En | MEDLINE | ID: mdl-35333347
ABSTRACT

BACKGROUND:

Pediatric international travelers account for nearly half of measles importations in the United States. Over one third of pediatric international travelers depart the United States without the recommended measles-mumps-rubella (MMR) vaccinations 2 doses for travelers ≥12 months and 1 dose for travelers 6 to <12 months.

METHODS:

We developed a model to compare 2 strategies among a simulated cohort of international travelers (6 months to <6 years) (1) No pretravel health encounter (PHE) travelers depart with baseline MMR vaccination status; (2) PHE MMR-eligible travelers are offered vaccination. All pediatric travelers experience a destination-specific risk of measles exposure (mean, 30 exposures/million travelers). If exposed to measles, travelers' age and MMR vaccination status determine the risk of infection (range, 3%-90%). We included costs of medical care, contact tracing, and lost wages from the societal perspective. We varied inputs in sensitivity analyses. Model outcomes included projected measles cases, costs, and incremental cost-effectiveness ratios ($/quality-adjusted life year [QALY], cost-effectiveness threshold ≤$100 000/QALY).

RESULTS:

Compared with no PHE, PHE would avert 57 measles cases at $9.2 million/QALY among infant travelers and 7 measles cases at $15.0 million/QALY among preschool-aged travelers. Clinical benefits of PHE would be greatest for infants but cost-effective only for travelers to destinations with higher risk for measles exposure (ie, ≥160 exposures/million travelers) or if more US-acquired cases resulted from an infected traveler, such as in communities with limited MMR coverage.

CONCLUSIONS:

Pretravel MMR vaccination provides the greatest clinical benefit for infant travelers and can be cost-effective before travel to destinations with high risk for measles exposure or from communities with low MMR vaccination coverage.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Rubéola (Sarampo Alemão) / Sarampo / Caxumba Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Rubéola (Sarampo Alemão) / Sarampo / Caxumba Idioma: En Ano de publicação: 2022 Tipo de documento: Article